NewGenIvf Group
A speculative $3–$5 post-split price scenario by December 2026, following the 1-for-4 reverse split effective Monday, October 12.
NASDAQ: NIVF · Updated October 14, 2026 · Speculative editorial outlook · High risk
The post-split opportunity
NewGenIvf is pursuing opportunities beyond its fertility-services foundation, including cell-sorting equipment, artificial intelligence, real estate and digital assets. Successful execution, disciplined use of new capital and progress on debt restructuring could support the bullish case.
Our speculative December 2026 scenario: $3–$5 per post-split share. This is a user-requested editorial forecast, not a valuation established by verified analyst research. We have not verified a published forecast supporting attribution of this range to Wall Street journalists or Seeking Alpha experts. It is not company guidance or analyst consensus.
Confirmed: Monday’s 1-for-4 reverse split
NewGen’s October 7 SEC filing states that its reverse stock split became effective at 12:01 a.m. Eastern Time on Monday, October 12, 2026, with split-adjusted Nasdaq trading beginning that morning. Every four existing shares were combined into one share. The ticker remains NIVF, with new CUSIP G0544E600.
A reverse split changes the share count and per-share price mechanically; it does not itself increase the value of an investor’s holding. The earlier $0.09 quote was a historical, user-supplied pre-split snapshot—not a current post-split quote. It is no longer used as the starting point for this forecast or a 10× return claim.
Read the October 7 split filingCompany press release: financing and growth plans
The latest release listed on NewGen’s investor-news page when reviewed on October 14 is “NewGen Announces Closing of $1.25 Million Public Offering.” Posted September 30 and datelined October 1, it says the transaction closed September 30, 2026, with approximately $1.25 million in gross proceeds before fees and expenses.
The offering covered 17,857,143 pre-split shares or pre-funded warrants: 125,000 shares and warrants for up to 17,732,143 shares. The pre-split price was $0.07 per share, or $0.06999 per pre-funded warrant plus a $0.00001 exercise price. These historical offering figures are not current market quotes.
Planned uses of net proceeds include investment in K25.ai, restructuring debt securities, working capital, manufacturing and deploying Nodexus cell-sorting machines, and general corporate purposes. The release does not state that all debt has been eliminated or provide a $3–$5 price target.
AI expansion: NIVF’s investment in K25.ai
In the October 13, 2026 Tickeron article “NIVF vs VCIG: Two Micro-Caps Navigating AI and Digital Asset Shifts,” author John Y White describes NewGen’s pivot toward AI and digital assets through its stake in K25.ai, an AI-powered live-streaming prediction-market platform. The article highlights this investment as a possible catalyst, while noting concentration risk, volatility and ongoing capital raises.
The article describes an investment stake—not a completed merger with K25.ai, and not a merger between NIVF and VCIG. It does not support the $3–$5 December forecast. Its reference to a 1-for-3 reverse split should not be used for the October 12 event: NewGen’s October 7 SEC filing specifies 1-for-4.
Read the Tickeron article: NIVF vs VCIGMerger status: what is confirmed
A new completed merger has not been verified in the sources reviewed. NewGen’s previously announced reverse merger with European Wellness Investment Holdings Limited was terminated on March 31, 2025, after required draft audited financial statements were not delivered. Investments and business-expansion plans should not be described as a completed merger.
Read the merger termination releaseThree reasons investors are watching
Life-science roots
NewGen’s legacy IVF and assisted-reproduction services provide its healthcare foundation. The company is also pursuing Nodexus cell-sorting machine deployment.
Technology-led opportunities
The company’s announced strategy includes investment in K25.ai, real-estate development, digital assets and reproductive health. These are growth opportunities, not guaranteed results.
Capital for execution
The September 30 offering raised approximately $1.25 million gross, with planned uses including debt restructuring, working capital and cell-sorting equipment.
By December 2026
An editorial upside scenario—not company guidance, verified Wall Street or Seeking Alpha research, or a guaranteed return.
What could go wrong
- • A reverse split alone does not improve operating results or create shareholder value.
- • Share offerings, warrants and convertible securities can dilute existing holders.
- • Debt restructuring is not the same as eliminating all company debt.
- • Execution across several businesses is uncertain, and the $3–$5 scenario may never be reached.
Important disclosure. This independent article is not issued or endorsed by NewGenIvf. The $3–$5 December 2026 forecast is a user-supplied, speculative editorial scenario expressed on a post-split basis—not company guidance, a verified expert forecast or a promised return. No current stock price or return multiple is asserted. Merger completion and third-party forecast attribution have not been verified. This is not financial advice. Review current filings and live market data before investing.